NNOX stock touches 52-week low at $4.07 amid market challenges

Published 07/04/2025, 14:52
NNOX stock touches 52-week low at $4.07 amid market challenges

Nano X Imaging Ltd (NASDAQ:NNOX) stock has reached a new 52-week low, trading at $4.07, as the company faces ongoing market headwinds. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 5.63 and more cash than debt on its balance sheet. This latest price point underscores a significant downturn for the medical imaging technology firm, which has seen its stock value decrease by 63.99% over the past year. With a market capitalization of $243 million and a beta of 2.03 indicating high volatility, investors are closely monitoring the company's performance. While the current trading level reflects a yearly low, InvestingPro analysis suggests the stock is currently undervalued, with analysts projecting 104% revenue growth. For comprehensive insights and 13 additional ProTips, explore the detailed Pro Research Report available on InvestingPro.

In other recent news, Nano-X Imaging reported its financial results for the fourth quarter of 2024, revealing a year-over-year revenue increase to $3 million, primarily driven by a 23% growth in teleradiology services. Despite this revenue growth, the company experienced a wider GAAP net loss of $14.1 million compared to $10.2 million in Q4 2023. The revenue from the company's AI solutions slightly decreased by 1% year-over-year, generating $83,000. Additionally, income from the sales and deployment of imaging systems added $136,000, with notable deployments in the United States and Africa.

Cantor Fitzgerald maintained an Overweight rating on Nano-X Imaging but reduced the price target from $12.00 to $9.00, citing the company's potential for increased U.S. deployments and the introduction of new devices under FDA review. The firm remained optimistic about Nano-X Imaging's future performance despite the target reduction. The company is actively expanding its market presence in the U.S. and Europe, with strategic advancements including FDA clearance and CE Mark for key products. Nano-X Imaging plans to focus on commercialization efforts in 2025, aiming to expand its client base for AI solutions and continue the FDA clearance process for new systems.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.